Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96,735 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
Stubbs MC, Burn TC, Sparks R, Maduskuie T, Diamond S, Rupar M, Wen X, Volgina A, Zolotarjova N, Waeltz P, Favata M, Jalluri R, Liu H, Liu XM, Li J, Collins R, Falahatpisheh N, Polam P, DiMatteo D, Feldman P, Dostalik V, Thekkat P, Gardiner C, He X, Li Y, Covington M, Wynn R, Ruggeri B, Yeleswaram S, Xue CB, Yao W, Combs AP, Huber R, Hollis G, Scherle P, Liu PCC. Stubbs MC, et al. Among authors: liu h, liu xm, liu pcc. Clin Cancer Res. 2019 Jan 1;25(1):300-311. doi: 10.1158/1078-0432.CCR-18-0098. Epub 2018 Sep 11. Clin Cancer Res. 2019. PMID: 30206163
Differential expression of C5aR1 and C5aR2 in innate and adaptive immune cells located in early skin lesions of bullous pemphigoid patients.
Emtenani S, Holtsche MM, Stahlkopf R, Seiler DL, Burn T, Liu H, Parker M, Yilmaz K, Dikmen HO, Lang MH, Sadik CD, Karsten CM, van Beek N, Ludwig RJ, Köhl J, Schmidt E. Emtenani S, et al. Among authors: liu h. Front Immunol. 2022 Nov 18;13:942493. doi: 10.3389/fimmu.2022.942493. eCollection 2022. Front Immunol. 2022. PMID: 36466856 Free PMC article.
Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study.
Hamadani M, Coleman M, Boccia R, Duras J, Hutchings M, Zinzani PL, Cordoba R, Oreiro MB, Williams V, Liu H, Stouffs M, Langmuir P, Sancho JM. Hamadani M, et al. Among authors: liu h. Hematol Oncol. 2023 Dec;41(5):848-857. doi: 10.1002/hon.3209. Epub 2023 Jul 26. Hematol Oncol. 2023. PMID: 37496298 Clinical Trial.
A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma.
Zha J, Chen Q, Zhang W, Jing H, Ye J, Liu H, Yu H, Yi S, Li C, Zheng Z, Xu W, Li Z, Lin Z, Ping L, He X, Zhang L, Xie Y, Chen F, Sun X, Su L, Zhang H, Yang H, Zhao W, Qiu L, Li Z, Song Y, Xu B. Zha J, et al. Among authors: liu h. Biomark Res. 2025 Jan 3;13(1):2. doi: 10.1186/s40364-024-00716-4. Biomark Res. 2025. PMID: 39754201
96,735 results
You have reached the last available page of results. Please see the User Guide for more information.